U.S. FDA approved Sanofi-Aventis Admelog (insulin lispro) Injection for the treatment type 1 and type 2 diabetes
U.S. FDA (Food and Drug Administration) announced that it granted final approval to Sanofi-Aventis U.S. LLC’s Admelog (insulin lispro) Injection for the treatment of patients with type 1 and type 2 diabetes.
Company: Sanofi-Aventis U.S. LLC
Brand Name: Admelog
Treatment for: Diabetes Type 1, Diabetes Type 2
Dosage Form: Injection
Generic name: insulin lispro
General information about Admelog
Admelog (insulin lispro) is a follow-on rapid-acting human insulin analog (referenced to Humalog) for the treatment of patients with type 1 and type 2 diabetes.
Admelog is rapid-acting insulin similar to Humalog®, another insulin lispro 100 Units/mL, currently approved in the U.S. The Admelog clinical development program involved more than 1,000 adults living with type 1 or type 2 diabetes. Prescription Admelog is a fast-acting human insulin used to improve blood sugar control in adults with Type 2 diabetes and adults and children (3 years and older) with Type 1 diabetes. Admelog will be available in both vials and the SoloStar pen, which is the most-used disposable insulin pen platform in the U.S.